Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 3/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TAF1 | P21675 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289505 | 0.90 | CHEK1 (0.57) | POLBMAP3K11GHSRBRD4FASN | |
| SCHEMBL4290168 | 0.88 | CHEK1 (0.49) | GHSRBRD4JAK2CHEK1TAF1 | |
| SCHEMBL13662731 | 0.85 | MAP3K11 (0.47) | POLBMAP3K11GHSRBRD4FASN | |
| SCHEMBL4295657 | 0.80 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL4288965 | 0.80 | CHEK1 (0.50) | CHEK1 | |
| SCHEMBL4291923 | 0.80 | CHEK1 (0.50) | POLBCHEK1 | |
| SCHEMBL4297137 | 0.79 | CHEK1 (0.56) | GHSRBRD4JAK2CHEK1BTK | |
| SCHEMBL4298796 | 0.77 | PIM1 (0.44) | CHEK1 | |
| SCHEMBL4295756 | 0.76 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL4289731 | 0.75 | CHEK1 (0.64) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904449-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-02 | — | — | EP | claimed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| EP-1904449-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008502-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258852-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, CDKN1A | POLB 841/4885MAP3K11 185/4885GHSR 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.